Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Indivior ( (INDV) ) has shared an announcement.
On January 8, 2026, Indivior issued full-year 2026 financial guidance, projecting total net revenue between $1.125 billion and $1.195 billion, with SUBLOCADE net revenue expected at $905 million to $945 million, non-GAAP operating expenses of $430 million to $450 million, and adjusted EBITDA of $535 million to $575 million, implying strong margin expansion driven by growth in SUBLOCADE dispense units and a simplified operating model. The company reported completing Phase I of its Indivior Action Agenda in 2025—generating momentum by growing U.S. SUBLOCADE revenue, simplifying the organization and transforming its operating model to deliver at least $150 million in annual non-GAAP operating expense savings—and said it entered Phase II, “Accelerate,” on January 1, 2026, while also highlighting its December 22, 2025 inclusion in the S&P SmallCap 600 index, shareholder approval to redomicile from the U.K. to the U.S. with the new parent Indivior Pharmaceuticals, Inc. expected on January 26, 2026, and the full settlement of a legacy U.S. Department of Justice obligation of $295 million, collectively reinforcing its financial flexibility, U.S. market focus and standing with investors and regulators.
The most recent analyst rating on (INDV) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.
Spark’s Take on INDV Stock
According to Spark, TipRanks’ AI Analyst, INDV is a Neutral.
The score is driven by strong technical momentum and an improved operating outlook (raised guidance and SUBLOCADE strength). This is tempered by elevated financial-risk signals from negative equity and historical earnings/cash-flow volatility, plus a relatively high P/E with no dividend yield support.
To see Spark’s full report on INDV stock, click here.
More about Indivior
Indivior is a specialty pharmaceuticals company focused on developing and commercializing medicines for opioid use disorder (OUD). Building on an established portfolio of OUD treatments and a dedicated pipeline in this category, the company aims to expand access to evidence-based therapies and position OUD as a recognized and treated chronic disease, with a significant commercial emphasis on its long-acting injectable product SUBLOCADE.
Average Trading Volume: 2,463,769
Technical Sentiment Signal: Buy
Current Market Cap: $4.52B
For a thorough assessment of INDV stock, go to TipRanks’ Stock Analysis page.